SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy

Maria Teresa Sandri[1¶], Elena Azzolini[1¶], Valter Torri[2], Sara Carloni[3], Chiara Pozzi[1], Michela Salvatici[1], Michele Tedeschi[1], Massimo Castoldi[5], Alberto Mantovani[1,3,4] and Maria Rescigno[1,3*]

[1]Humanitas Clinical and Research Center – IRCCS, Rozzano – Milan, Italy

[2]Istituto di Ricerche Farmacologiche "Mario Negri" - IRCCS, Milano, Italy

[3]Humanitas University Department of Biomedical Sciences, Pieve Emanuele – Milan, Italy

[4]The William Harvey Research Institute, Queen Mary University of London, London, UK

[5]Humanitas Gavazzeni and Castelli, Bergamo, Italy

¶These authors contributed equally

* Corresponding author

E-mail: maria.rescigno@hunimed.eu

Abstract

Lombardy is the Italian region most affected by COVID-19. We tested the presence of plasma anti-SARS-CoV-2 IgG antibodies in 3985 employees across 7 healthcare facilities in areas of Lombardy with different exposure to the SARS-CoV-2 epidemic. Subjects filled a questionnaire to self-report on COVID-19 symptoms, co-morbidities, smoking, regular or smart-working, and the exposure to COVID-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical location of the facility, ranging between 3 and 43%, consistent with the spatial variation of COVID-19 incidence in Lombardy, and correlated with family contacts. We observed a higher prevalence of females than males positive for IgG, however the level of antibodies was similar, suggesting a comparable magnitude of the response. IgG positivity among smokers was lower (7.4% vs 13.5%) although without difference in IgG plasma levels. We observed 11.9% of IgG positive asymptomatic individuals and another 23.1% with one or two symptoms. Interestingly, among the IgG positive population, 81.2% of subjects with anosmia/dysgeusia and fever were SARS-CoV-2 infected, indicating that these symptoms are strongly associated to COVID-19. The plasma level of IgG inversely correlated with anti-pneumococcal vaccination.

In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the geographical exposure to the virus and primarily to family rather than hospital exposure.

Introduction

Lombardy has been the Italian region most affected by SARS-Cov-2 infection with more than 80,000 cases from the outbreak and a mortality rate of nearly 18% (as of May 8th, https://utils.cedsdigital.it/coronavirus/#regioni1). Only symptomatic individuals have been tested by RT-PCR to detect SARS-CoV-2, and hence the spreading of the virus, particularly in the asymptomatic population, is unknown. Detection of viral RNA is not very sensitive in cases of low viral load, when patients with negative RT PCR test convert to positive in few days, or when COVID-19 is highly suspected by the result of chest CT [1-6]. It is just a snapshot of the exact moment of the infection. Hence, unless being continuously monitored by viral testing, the asymptomatic individuals' infected state may be missed.

A retrospective way to assess viral spread is via the analysis of an immune response that can be detected through the development of immunoglobulins [7]. Indeed, almost the totality (>95%) of laboratory-confirmed COVID-19 showed seroconversion even using different methodologies and antibody isotypes (ELISA, EIA, anti-IgM, anti-IgG or anti-IgA) [7-11]. Interestingly, the dynamic of the immune response to SARS-CoV-2 is very peculiar and patient dependent. IgM for instance, which should be the first type of immunoglobulins to appear under normal circumstances, are detected before, concomitant or even after IgGs, or do not appear at all [7,12]. This suggests that differently from other infectious diseases, in SARS-CoV-2 infection, IgG is a more reliable marker for seroconversion than IgM.

There is evidence that IgG analysis allowed to detect viral RNA negative asymptomatic relatives of COVID-19 patients [7], suggesting that anti-SARS-CoV-2 IgG may be used as a diagnostic tool to detect the incidence of asymptomatic infections even in cases of impossibility of viral detection. Based on these assumptions, we tested the presence of plasma anti-SARS-CoV-2 IgG antibodies in nearly 4000 (3985) employees of 7 different healthcare facilities, one including a research center and

61 a University, located across the Lombardy region in areas with different exposure to the epidemic
62 (Milan, Rozzano, Varese, Castellanza and Bergamo (the city most affected by the pandemic per
63 number of individuals)). All of the analyzed hospitals drastically reduced their routine practice and,
64 except for Humanitas Medical Care, which is a point of care, they were all dedicated to COVID-19
65 during the time of observation.
66

67 ## Results

68 **Study population**

69 Recruitment was on a voluntary basis: it started on April 28th and more than 65% of employees
70 participated as of May 16th, 2020 (clinicaltrial.gov NCT04387929). An international medical school
71 (Humanitas University, Pieve Emanuele (MI)) and 6 different hospitals participated to the study:
72 Istituto Clinico Humanitas (ICH), Rozzano (MI); Humanitas Gavazzeni, Bergamo; Humanitas
73 Castelli, Bergamo; Humanitas Mater Domini (HMD), Castellanza (VA); Humanitas Medical Care
74 (HMC), Varese (VA); Humanitas San Pio X, Milano (MI). The individuals were healthcare
75 professionals (physicians (16.5%), surgeons (7.2%) anesthesiologists (2.8%), physiotherapists
76 (1.8%), nurses (25.4%)), technicians (4.4%), students (0.7%), researchers/academics (3.1%), other
77 roles, including administrative staff (7.9%), biologists (1.3%) etc.. 66.8% were females and 33.2%
78 males, median age 42 yo (21-86 yo) (Supplementary Table S1). The distribution of the healthcare
79 workers participating to the study among the different hospitals was very similar except for HMC, a
80 point of care, where the proportion of workers differs from that of the other hospitals, and for ICH
81 which is the only site where researchers work (Supplementary Fig. S1). Besides this, we did not
82 observe major differences in the voluntary participation of the different professionals across sites.
83 Subjects filled a questionnaire reporting whether they had COVID-associated symptoms, including
84 fever, dry cough, asthenia, soreness and muscle pain, runny nose, sore throat, gastrointestinal

85 symptoms (including vomiting, nausea, diarrhea), conjunctivitis, pneumonia, severe acute respiratory
86 syndrome, anosmia/dysgeusia from February 1st to the time of questionnaire filling. They also
87 reported on body mass index (BMI), co-morbidities (hypertension, heart disease or diabetes,
88 immunosuppression), smoking, vaccinations, regular or smart-working, the frequency of home exits
89 for non-work related reasons and the exposure to COVID-infected individuals. With the exception of
90 HMC, which being a point of care closed down at lockdown (officially started on March 9th), during
91 the pandemic and in the period of observation, most of routine practice was interrupted, and the
92 majority of physician and non-physician healthcare professionals worked in COVID-dedicated areas
93 independent on the location of the hospital (for instance at ICH, 8 out of 20 wards were transformed
94 into COVID treatment wards (330 beds), and 2 into semi-intensive care units, while the intensive care
95 units (ICU) capacity doubled (60 beds)). All of the personnel working in the emergency room or
96 customer care had to wear obligatory PPE from February 1st at Castelli and Gavazzeni, from February
97 23rd at ICH, and from March 3rd everywhere in the hospital. Administrative staff workers stopped
98 working in the hospital at the beginning of lockdown and worked from home. Customer service and
99 research personnel worked one or two days a week at the sites and the rest of the time from home.
100

101 **Frequency of IgG positivity and correlation with geographical area**

102 Anti-S1 and anti-S2 SARS-CoV-2 IgG specific antibodies were detected via an indirect
103 chemiluminescence immunoassay. According to kit manufacturer, the test discriminates among
104 negative (<12AU/mL; with 3.8 as the limit of IgG detection), equivocal (12.0 – 15.0 AU/mL) and
105 truly positive (>15.0 AU/mL) subjects. Of 3985 enrolled subjects, 3462 (87%) were negative, 76
106 (2%) equivocal and 447 (11%) positive (which together with equivocal summed up to 523 (13%))
107 (Supplementary Table S1). We decided to group together equivocal and truly positive subjects as
108 they behaved very similarly both as separate groups or as grouped together (Positive - IgG ≥ 12.0

109 AU/ml) in subsequent analyses (for instance in correlation with the number of symptoms, as shown
110 in Supplementary Fig. S2).
111 The number of individuals exposed to the virus reflected the geographical area where the healthcare
112 facility was located (Fig. 1). Two hospitals based in Bergamo (Humanitas Gavazzeni and Castelli)
113 were the most affected as between 35 and 43 % of the subjects was IgG positive. In the other sites
114 the frequency of IgG positivity ranged between 3% (HMC) and 9% (ICH) (Supplementary Table S2).
115 We applied a hierarchical (multilevel) model adjusting for clustering of individuals within healthcare
116 facilities when assessing overall relationships between locations, professional status and the analyzed
117 variables. Humanitas Gavazzeni in Bergamo was significantly different from all other facilities
118 except for Castelli in Bergamo (Table 1 and Supplementary Fig. S3, $p<0.0001$,OR and 95%CI
119 indicated in the table). Interestingly, HMC and HMD which had the lowest incidence of IgG positive
120 individuals (3% and 3.8%, respectively), are located in Varese, which is one of the less COVID-19
121 affected province in Lombardy (https://www.lombardianotizie.online/coronavirus-casi-lombardia/).
122 In agreement, the percentage of patients hospitalized for COVID-19 was higher in Bergamo at
123 Gavazzeni (56%), intermediate in Milan at ICH (36%) and low in Varese at HMD (10%) (not shown).

Table 1 Logistic analysis for site effect

Comparison	Odds ratio estimates	Lower 95% CI	Upper 95% CI	p-value
Humanitas Rozzano (ICH)	0.181	0.146	0.226	<.0001
Humanitas University (HU)	0.156	0.062	0.396	
Humanitas Medical Care (HMC)	0.057	0.014	0.234	
Humanitas San Pio X	0.126	0.074	0.215	
Humanitas Mater Domini (HMD)	0.073	0.041	0.131	
Humanitas Castelli	1.384	0.943	2.032	
Humanitas Gavazzeni - ref	1.00			

124
125

126 **Frequency of IgG positivity and correlation with gender, BMI and smoking**

127 IgG positivity (≥12 AU/mL) was different between males (11.4%) and females (14%)
128 (Supplementary Table S1), and, as shown in Table 2a, this difference was retained in the multilevel
129 logistic analysis (OR=0.73; 95%CI 0.57-0.94, p=0.016). Thus, the observed effect was associated to
130 a difference in gender sensitivity to infection or to the ability to mount an antibody response rather
131 than to a bias of the recruitment itself.

132 Interestingly, IgG positivity among smokers was lower (7.4% vs 13.5%) (OR=0.45; 95%CI 0.34-
133 0.60, p<0.0001, Supplementary Fig. S4) confirming the trend effect observed with the multilevel
134 logistic analysis (OR=0.48; 95%CI 0.38-0.61, p<0.0001, Table 2a). On the contrary, there was no
135 statistically significant difference according to BMI (Table 2a).

Table 2a Multilevel Logistic model for age, gender and their interaction, smoking habits, BMI

Comparison	Odds ratio estimates	Lower 95% CI	Upper 95% CI	p-value
Physician vs Other Role	1.10	0.79	1.53	0.5039
Surgeon vs Other Role	1.10	0.71	1.71	
Anesthesiologist vs Other Role	0.49	0.22	1.08	
Physiotherapist vs Other Role	1.17	0.56	2.46	
Nurse vs Other Role	1.16	0.87	1.55	
Researcher vs Other Role	0.94	0.47	1.90	
Biologist vs Other Role	0.69	0.20	2.37	
Student vs Other Role	1.07	0.29	3.95	
Radiology Technician vs Other Role	0.53	0.25	1.13	
Lab. Technician vs Other Role	0.75	0.31	1.86	
Staff vs Other Role	1.04	0.67	1.61	
Smoking (Number of cigarettes/day)	0.48	0.38	0.61	<.0001
Age >60 vs ≤60	0.35	0.15	0.83	0.0166
Gender male vs female	0.73	0.57	0.94	0.0158
Interaction Age*Gender	2.98	1.08	8.21	0.0352
BMI	1.11	0.98	1.26	0.1127

136

137

138 **Frequency of IgG positivity and correlation with age**

139 We then evaluated whether there was a difference in the positivity to IgG according to age. We found
140 that there was a Gaussian distribution of the number of IgG positive (≥12 AU/mL) individuals across
141 the age range (Fig. 2a), but then when analyzing the frequency of positivity at the different age ranges
142 we observed an age dependent reduction of IgG positive individuals (Fig. 2b). However, this age-
143 dependency was primarily due to the female rather than the male population, particularly for subjects
144 either young (20-40 yo) or older than 60 yo (test for heterogeneity of trend effect age between male
145 and female p=0.0024 Fig. 2b). In older than 60 yo, IgG positivity dropped from 12% in males to 5%
146 in females (Table 2a and Fig. 2b). This indicates that females are more likely to be infected – or to
147 induce an IgG response - when young, and less likely at ages higher than 60 yo.

148

149 **Frequency of IgG positivity and correlation with viral positivity at time of testing**

150 Following the guidelines of the national health system, all 523 subjects with IgG ≥ 12 AU/ml
151 underwent a rinopharyngeal swab for SARS-CoV-2 RNA viral detection. We found that 39 (7.6%)
152 individuals resulted positive for viral RNA detection (Table 3). However, in 31 of these (79.5%), the
153 subjects tested negative for at least one of the genomic sequences of the three SARS-CoV-2 gene
154 targets: *E, RdRp* and *N*. To rule out that the negative population (3.8<IgG<12 AU/mL) comprised
155 individuals in the early phases of viral infection, a sample of 283 (35.4%) individuals underwent a
156 rinopharyngeal swab for SARS-CoV-2 RNA viral detection. All of them resulted negative to the swab
157 confirming the negativity of the test below 12 AU/mL (Table 3).

158

Table 3 Rinopharyngeal swab positivity in relation to IgG positivity

	Total		Rinopharyngeal swab results											
			Negative			Positive low load			Positive			Positive low load + Positive		
	N	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total
IgG results														
Negative (3.8<IgG<12AU/mL)	283	35.4	283	100.0	37.2	.	.	.	.	.	.	.	.	.
Equivocal (12÷15AU/mL)	75	9.4	70	93.3	9.2	3	4.0	9.7	2	2.7	25.0	5	6.7	12.8
Truly Positive (>15AU/mL)	441	55.2	407	92.3	53.6	28	6.3	90.3	6	1.4	75.0	34	7.7	87.2
Positive (≥12AU/mL)	516	64.6	477	92.4	62.8	31	6.0	100.0	8	1.6	100.0	39	7.6	100.0
Total	799	100.0	760	95.1	100.0	31	3.9	100.0	8	1.0	100.0	39	4.9	100.0

159

160 **Frequency of IgG positivity and correlation with professional status**

161 We then evaluated the proportion of IgG positive individuals (≥ 12 AU/mL) across the different
162 professional workers and found that there was no statistically significant difference when taking into
163 account age, gender and their interaction, smoking habits, BMI and location (Table 2a) even though
164 some professionals worked from home from the beginning of lockdown (such as the administrative
165 staff), suggesting that their exposure to the virus was not occurring at work. We thus assessed which
166 could have been the major driver of transmission of the virus on the basis of the self-reported
167 questionnaire. We found heterogeneity of IgG positivity among drivers (p<0.0001). Compared with
168 group referring no contact, IgG positivity correlated most with family contacts (OR=4.73; 95%CI
169 2.93-7.65), and not with either a colleague or a patient, suggesting that this was likely the major cause
170 of viral exposure (Tables 4a-b). This finding is in line with a recent report on testing the serology of
171 healthcare workers and their families [13].

Table 4a Association of contacts with IgG positivity										
	Total		IgG results							
			Negative (<12AU/mL)		Equivocal (12÷15AU/mL)		Truly Positive (>15AU/mL)		Positive (≥12AU/mL)	
	N	% of total	N	%	N	%	N	%	N	%
Contagion Modality										
None	1073	27.0	1010	94.1	11	1.0	52	4.8	63	5.9
Colleague	853	21.5	740	86.8	20	2.3	93	10.9	113	13.2
Patient	1599	40.2	1346	84.2	31	1.9	222	13.9	253	15.8
Family member	138	3.5	95	68.8	7	5.1	36	26.1	43	31.2
Other	310	7.8	262	84.5	7	2.3	41	13.2	48	15.5
Total	3973	100.0	3453	86.9	76	1.9	444	11.2	520	13.1

172

Table 4b Summary measures of association of contacts with IgG positivity			
Contagion Modality	**Odds ratio**	**95% CI**	
None	Ref		
Colleague	1.59	1.11	2.27
Patient	1.83	1.29	2.60
Family member	4.73	2.93	7.65
Other	2.05	1.32	3.18
P value (Wald test)	<0.0001		
Multilevel logistic analysis, considering subjects nested in the hospital site. Adjusted for role, age (cut off=60 years) gender, BMI, smoking habits.			

173

174 **Frequency of IgG positivity and correlation with symptoms, comorbidities and vaccinations**

175 We then evaluated whether there was a correlation between the number and typology of self-reported
176 symptoms and the frequency of antibody response both as number of individuals (Fig. 3a and 3b) and
177 as percentage on the whole population (Fig. 3c and 3d). As shown in Figure 3, when analyzing
178 individuals deemed to be positive on the basis of the amount of IgG (≥12 AU/mL) we observed a two
179 phases decay: first a similar frequency (a) or number (c) of subjects with 0 to 7 concomitant
180 symptoms, and then a drop of individuals at higher number of concomitant symptoms. This
181 distribution followed a sigmoidal, four parameter logistic curve whereby X is the number of

182 symptoms (R^2=0.97). By contrast, in the population with IgG <12 AU/mL we found a higher number
183 (b) or frequency (d) of individuals with 0, 1 or 2 symptoms and the distribution was following an
184 exponential curve (R^2=0.9975). The multilevel logistic analysis showed that, besides pneumonia,
185 among the symptoms, fever, anosmia/dysgeusia (loss of smell or taste) and chest pain were those that
186 best characterized the IgG positive population, particularly when collated (Table 2b).

Table 2b Multilevel Logistic model for symptoms adjusted for professional status, age, gender and their interaction, smoking habits, BMI

Comparison	Odds ratio estimates	Lower 95% CI	Upper 95% CI	p-value
Fever	5.79	3.58	9.36	<.0001
Low-grade Fever	1.41	0.86	2.33	0.1735
Cough	1.08	0.69	1.71	0.7266
Sore Throath/Runny nose	0.93	0.61	1.42	0.7332
Muscle pain	1.31	0.83	2.06	0.2453
Asthenia	0.92	0.57	1.47	0.7263
Anosmia/Dysgeusia	11.51	7.06	18.77	<.0001
Gastrointestinal disorders	0.77	0.49	1.18	0.2299
Conjunctivitis	1.35	0.77	2.36	0.2887
Dyspnea	1.14	0.64	2.06	0.6539
Chest pain	2.17	1.26	3.74	0.0055
Tachycardia	0.64	0.38	1.09	0.0999
Pneumonia	9.00	1.34	60.66	0.0240

187

188 Indeed, dividing the population according to the number of symptoms, IgG positivity increased from
189 11.9% in the absence of symptoms to 42.8% in the presence of 5 symptoms or more (Table 5), and
190 the value of the AUC derived by the multivariable model was 79%, while the combination of just
191 fever versus anosmia/dysgeusia had an AUC of 78% (Supplementary Fig. S5). 81.2% of individuals
192 presenting both anosmia/dysgeusia and fever resulted SARS-CoV-2 infected. The sensitivity,
193 specificity and positive Likelihood ratio of anosmia/dysgeusia and fever were 25.6%, 99.1% and
194 28.6, respectively (Supplementary Table S3).

195 These results indicate that there are symptoms that best characterize the paucisymptomatic COVID-
196 19 population and that when individuals present with fever and anosmia/dysgeusia they are likely to
197 have SARS-CoV-2 infection.
198 Comorbidities (in particular cardiovascular diseases and metabolic syndrome) have been associated
199 to a worse prognosis of COVID-19 patients [14]. Hence we wanted to assess whether the presence of
200 comorbidities correlated with a different incidence of IgG positivity. However, when we analyzed if
201 there was any correlation between IgG positivity and comorbidities, we could not detect any
202 (Supplementary Tables S4a and S4b). The same was true for the number or type of vaccination (flu,
203 pneumococcus, tuberculosis or other vaccines) (Supplementary Tables S5a and S5b).
204

Table 5 Association of symptoms with IgG positivity

	Total		IgG results											
			Negative (<12AU/mL)			Equivocal (12÷15AU/mL)			Truly Positive (>15AU/mL)			Positive (≥12AU/mL)		
	N	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total
Fever														
No	3488	87.5	3179	91.1	91.8	56	1.6	73.7	253	7.3	56.6	309	8.9	59.1
Yes	497	12.5	283	56.9	8.2	20	4.0	26.3	194	39.0	43.4	214	43.1	40.9
Low-grade Fever														
No	3557	89.3	3149	88.5	91.0	63	1.8	82.9	345	9.7	77.2	408	11.5	78.0
Yes	428	10.7	313	73.1	9.0	13	3.0	17.1	102	23.8	22.8	115	26.9	22.0
Cough														
No	3074	77.1	2750	89.5	79.4	57	1.9	75.0	267	8.7	59.7	324	10.5	62.0
Yes	911	22.9	712	78.2	20.6	19	2.1	25.0	180	19.8	40.3	199	21.8	38.0
Sore Throat/Runny nose														
No	2687	67.4	2391	89.0	69.1	50	1.9	65.8	246	9.2	55.0	296	11.0	56.6
Yes	1298	32.6	1071	82.5	30.9	26	2.0	34.2	201	15.5	45.0	227	17.5	43.4
Muscle pain														
No	2957	74.2	2707	91.5	78.2	42	1.4	55.3	208	7.0	46.5	250	8.5	47.8
Yes	1028	25.8	755	73.4	21.8	34	3.3	44.7	239	23.2	53.5	273	26.6	52.2
Asthenia														
No	3237	81.2	2948	91.1	85.2	43	1.3	56.6	246	7.6	55.0	289	8.9	55.3
Yes	748	18.8	514	68.7	14.8	33	4.4	43.4	201	26.9	45.0	234	31.3	44.7

Table 5 Association of symptoms with IgG positivity

	Total		IgG results											
			Negative (<12AU/mL)			Equivocal (12÷15AU/mL)			Truly Positive (>15AU/mL)			Positive (≥12AU/mL)		
	N	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total
Anosmia/Dysgeusia														
No	3617	90.8	3348	92.6	96.7	46	1.3	60.5	223	6.2	49.9	269	7.4	51.4
Yes	368	9.2	114	31.0	3.3	30	8.2	39.5	224	60.9	50.1	254	69.0	48.6
Gastrointestinal disorders														
No	3165	79.4	2812	88.8	81.2	52	1.6	68.4	301	9.5	67.3	353	11.2	67.5
Yes	820	20.6	650	79.3	18.8	24	2.9	31.6	146	17.8	32.7	170	20.7	32.5
Conjunctivitis														
No	3583	89.9	3145	87.8	90.8	64	1.8	84.2	374	10.4	83.7	438	12.2	83.7
Yes	402	10.1	317	78.9	9.2	12	3.0	15.8	73	18.2	16.3	85	21.1	16.3
Dyspnea														
No	3726	93.5	3291	88.3	95.1	67	1.8	88.2	368	9.9	82.3	435	11.7	83.2
Yes	259	6.5	171	66.0	4.9	9	3.5	11.8	79	30.5	17.7	88	34.0	16.8
Chest pain														
No	3664	91.9	3235	88.3	93.4	62	1.7	81.6	367	10.0	82.1	429	11.7	82.0
Yes	321	8.1	227	70.7	6.6	14	4.4	18.4	80	24.9	17.9	94	29.3	18.0
Tachycardia														
No	3553	89.2	3112	87.6	89.9	62	1.7	81.6	379	10.7	84.8	441	12.4	84.3
Yes	432	10.8	350	81.0	10.1	14	3.2	18.4	68	15.7	15.2	82	19.0	15.7
Pneumonia														
No	3951	99.1	3457	87.5	99.9	75	1.9	98.7	419	10.6	93.7	494	12.5	94.5
Yes	34	0.9	5	14.7	0.1	1	2.9	1.3	28	82.4	6.3	29	85.3	5.5
Other symptoms														
No	3828	96.1	3341	87.3	96.5	71	1.9	93.4	416	10.9	93.1	487	12.7	93.1
Yes	157	3.9	121	77.1	3.5	5	3.2	6.6	31	19.7	6.9	36	22.9	6.9
Number of symptoms														
0 symptoms	1380	34.6	1318	95.5	38.1	11	0.8	14.5	51	3.7	11.4	62	4.5	11.9
1 symptoms	814	20.4	758	93.1	21.9	10	1.2	13.2	46	5.7	10.3	56	6.9	10.7
2 symptoms	582	14.6	517	88.8	14.9	11	1.9	14.5	54	9.3	12.1	65	11.2	12.4
3 symptoms	411	10.3	350	85.2	10.1	10	2.4	13.2	51	12.4	11.4	61	14.8	11.7
4 symptoms	256	6.4	201	78.5	5.8	8	3.1	10.5	47	18.4	10.5	55	21.5	10.5
5 or more symptoms	542	13.6	318	58.7	9.2	26	4.8	34.2	198	36.5	44.3	224	41.3	42.8
Fever and anosmia/dysgeusia														
No	3285	82.4	3096	94.2	89.4	39	1.2	51.3	150	4.6	33.6	189	5.8	36.1

Table 5 Association of symptoms with IgG positivity

	Total		IgG results											
			Negative (<12AU/mL)			Equivocal (12÷15AU/mL)			Truly Positive (>15AU/mL)			Positive (≥12AU/mL)		
	N	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total
Anosmia/dysgeusia	203	5.1	83	40.9	2.4	17	8.4	22.4	103	50.7	23.0	120	59.1	22.9
Fever	332	8.3	252	75.9	7.3	7	2.1	9.2	73	22.0	16.3	80	24.1	15.3
Fever and anosmia/dysgeusia	165	4.1	31	18.8	0.9	13	7.9	17.1	121	73.3	27.1	134	81.2	25.6
Total	3985	100.0	3462	86.9	100.0	76	1.9	100.0	447	11.2	100.0	523	13.1	100.0

205

206

207 **IgG plasma levels and population characteristics**

208 The frequency of IgG positive (≥12 AU/mL) individuals clearly reflected the increased exposure to
209 the virus across the analyzed geographical areas, correlated with COVID-19-related symptoms and
210 showed a higher proportion of positivity within young females and non-smoker subjects. However,
211 an advantage of using a quantitative assay for IgG testing is that it is also possible to assess the
212 magnitude of the immune response. Hence, we analyzed the data also in relation to IgG plasma levels.
213 First, we assessed whether the level of plasma IgG correlated with positivity to the rinopharyngeal
214 swab. To take into account a possible temporal confounding factor of symptoms detection and
215 serological test, we compared the IgG plasma levels of swab positive or swab negative individuals
216 with that of the ascertained COVID-19 population (between the months of March and April). We
217 could not detect any statistically significant difference among IgG ≥12 subjects with rinopharyngeal
218 swab positive or negative and the COVID-19 populations, suggesting that the positivity to the swab
219 does not correlate with a higher IgG plasma level (Fig. 4a). However, we observed that physicians
220 (including anesthesiologists and physiotherapists) had a higher level of plasmatic IgG as confirmed
221 by statistically different odds ratios (Supplementary Table S6, p=0.02 and odds ratios in
222 Supplementary Fig. S6).

223

224 **IgG plasma levels BMI, gender and smoking**

225 As we observed a higher proportion of positivity (IgG≥12 AU/mL) within females that may indicate
226 either a higher exposure to the virus, a higher incidence of infection or a higher ability to mount an
227 immune response, we evaluated whether this difference was paralleled by increased IgG plasma
228 levels. We found out that there was no difference between IgG plasma levels of males versus females,
229 suggesting a similar magnitude of the immune response (Fig. 4b, Supplementary Table S6). However,
230 when assessing a difference of IgG plasma levels across age ranges, there was a trend towards an
231 increased level of plasma IgG towards the older age (p = 0.0002, total; p = 0.0085, females; p =
232 0.008, males) (Fig. 4c). The difference of IgG response between females and males in relation to age
233 remains quite intriguing and we still have to understand its relevance with the higher incidence of
234 COVID-19 in males [15]. Interestingly, while smoking seemed to inversely correlate with the frequency
235 of IgG positive individuals, it did not have any effect on IgG plasma levels (Supplementary Fig. S7a)
236 even in relation to the number of smoked cigarettes per day (Supplementary Fig. S7b and S6). On the
237 contrary, BMI, which was not influencing the frequency of IgG positive individuals, was affecting
238 the plasma concentration of IgG: the higher the BMI, the higher the level of IgG (Supplementary
239 Table S6, p= 0.0009)

240

241 **IgG plasma levels and symptoms**

242 As we have shown that the distribution of the IgG positive (≥12 AU/mL) population followed a
243 sigmoidal curve with a constant level of individuals up to 7 concomitant symptoms, we thus evaluated
244 whether there was also a correlation between the plasma level of IgG and the number of symptoms.
245 The distribution of IgG levels in the population versus the cumulative symptoms was very similar
246 when analyzing the whole population or those of ICH and Gavazzeni which had different proportions
247 of IgG positive individuals (Supplementary Fig. S8). They were characterized by similar areas under
248 the curve (All: 571; ICH: 550; Gavazzeni: 522) and the respective Receiver Operating Characteristics

249 (ROC) curves were perfect (100%), confirming maximal specificity and sensitivity of the IgG test at
250 IgG ≥12 AU/mL (Supplementary Fig. S8). Interestingly, we observed a direct correlation between
251 the number of concomitant symptoms and an increase in the level of plasma IgG (Fig. 5a,
252 Supplementary Table S7; CI are reported in the table for the different symptoms and combinations
253 thereof, $p<0.014$). By contrast, the level of IgG in the population with values < 12 AU/mL was
254 constant, regardless of the number of symptoms (Fig. 5b). When we analyzed the levels of IgG in
255 relation to symptoms, we found that those subjects reporting fever, anosmia/dysgeusia, or pneumonia
256 had all significant odds ratios (Fig. 5c). In addition, subjects with fever, cough, muscular pain,
257 asthenia, anosmia/dysgeusia, dyspnea, chest pain, tachycardia or pneumonia, they all had higher IgG
258 levels than those without symptoms (Supplementary Table S7, *p* values and CI are reported in the
259 table for the different symptoms). This confirms that presence of symptoms correlates with higher
260 IgG levels as shown in Fig. 5a. Further, combination of fever with anosmia/dysgeusia and/or dyspnea
261 characterized populations with higher IgG plasma levels (Supplementary Table S7, $p<0.0001$, CI are
262 reported in the table for the different symptoms and combinations thereof), also when considering the
263 whole population regardless of IgG positivity (Fig. 5d, $p<0.0001$ in a LR test for global null
264 hypothesis ordinal logistic analysis). When considering the level of IgG≥12 the distribution of IgG
265 plasma levels was very similar in subjects with these symptoms (Fig. 5e), however we found
266 statistically significant differences in odds ratios when combining fever with anosmia/dysgeusia and
267 fever with anosmia/dysgeusia and dyspnea (Fig. 5f, $p=0.0004$ in a LR test for global null hypothesis
268 ordinal logistic analysis). This confirms that these symptoms are the ones best characterizing SARS-
269 CoV-2 infection. No statistically significant differences in IgG plasma levels were observed in
270 relation to comorbidities. In steatosis/cirrhosis we had only two cases in which we found an inverse
271 correlation but this should be confirmed on a higher number of individuals ($p=0.0211$, CI 12.30-
272 12.70, Supplementary Table S8). Moreover, we observed an interesting inverse correlation between
273 pneumococcal vaccination and IgG plasma levels ($p=0.03$, CI 15-29.40, Supplementary Table S9).

Discussion

Here we report a comprehensive analysis of nearly 4000 individuals from different healthcare facilities representative of dramatically different levels of SARS-CoV-2 exposure in Lombardy, the most affected region by COVID-19 in Italy. We observed a range of positivity which strongly correlated with the geographical area of viral exposure from 3% in the Varese area to 43% in the Bergamo area, which were respectively the most or less COVID-affected Lombardy provinces. The proportion of IgG positive females was higher than that of males in all of the analyzed sites. However, we found a lower proportion of IgG positive individuals in females older than 60 years old than in age-matched males. This is quite intriguing as males and females are equally affected by COVID-19, but males have a worse prognosis [16]. Through the use of a quantitative antibody test of IgG we were also able to assess the magnitude of the immune response. We found that younger males (below 40 yo) displayed reduced IgG plasma levels than older males (from 41 yo onwards). This is in line with a recent report in COVID-19 patients showing that younger patients developed lower titers of IgG [17] and another one showing that higher IgG titers in the plasma of convalescent individuals were associated to older age and male sex [18]. Thus, also in the healthy population, younger males exposed to the virus develop a reduced antibody response. Hence, it is very important when analyzing the serology to SARS-CoV-2 to take into account both age and sex.

Our study differs from the one reported by Sood and colleagues in Los Angeles County[19] as we used a quantitative antibody test and analyzed a large hospital population which ranged from healthcare professionals, researchers and administrative staff from 7 different facilities. Indirectly, we show that it is rather the environment than the hospital professional exposure which dictates the probability of contracting SARS-CoV-2 infection. Indeed, we show a higher percentage of IgG positive individuals in areas with a higher incidence of COVID-19 and among subjects who had been in contact with COVID-19 affected relatives. Further, we observed a similar proportion of IgG positive individuals

298 among healthcare professionals functioning at hospital and administrative staff working from home.
299 However, the magnitude of the antibody response in terms of plasma levels of IgG was higher in
300 healthcare professionals suggesting that these individuals developed a more sustained immune
301 response. We were also able to pinpoint 11.9% of IgG positive individuals which were completely
302 asymptomatic and another 23.1% of paucisymptomatic subjects with 1 or 2 symptoms. This
303 percentage differs from that observed in two recent studies analyzing SARS-CoV-2 infection via viral
304 testing across different population types [20,21]. Among healthcare workers, 57% of the subjects were
305 asymptomatic/paucisymptomatic [20] while in a wider population in the Italian municipality of Vo'
306 Euganeo, that underwent lockdown soon after detecting the first case of COVID-19, the percentage
307 of asymptomatics was 42.5 [21]. This suggests that there is still a good proportion of individuals that
308 probably do not develop antibodies, or develop them at low/undetectable levels. This would be in line
309 with recent studies showing that IgG positivity is short-lived [22] and relatives of COVID-19 patients
310 carry T cells specific for SARS-CoV-2 but do not seroconvert, suggesting that also IgG positivity
311 may not detect all individuals exposed to the virus [23]. However, if we expand our analysis to
312 healthcare workers without symptoms but with IgG >3.8 AU/mL, and not simply those IgG ≥ 12
313 AU/mL, which are considered 'positive' by the manufacturer of the test, the percentage of positivity
314 raises to 40%. This may indicate that there may be different exposures to the virus which result in a
315 wide range of levels of antibody production, including those between 3.8 and 12 AU/mL. As in 283
316 subjects with IgG 3.8-12 AU/mL we performed a viral test, and it was negative, this indicates that
317 they probably were exposed to the virus earlier and succeeded in eliminating it without a strong
318 antibody response. Thus, it would be interesting to evaluate which serology test was used and which
319 cut-off value was considered for determining IgG positivity in studies where IgG responses were
320 negative, but T cell responses were present [23]. In addition, some of SARS-CoV-2 viral peptides
321 activated T cells also from unexposed individuals suggesting that some cross-reactivity could occur,
322 maybe in response to previous infections with common cold coronaviruses [24].

323 Among the symptoms, those that characterized most the IgG positive population were fever and
324 anosmia/dysgeusia. 81.2% of individuals presenting both anosmia/dysgeusia and fever resulted
325 SARS-CoV-2 infected, indicating that these symptoms are strongly associated to COVID-19.
326 Selected vaccines such as BCG have been suggested to increase pathogen-agnostic off-target
327 resistance to infectious agents [25]. However, a recent report showed no differences in incidence of
328 COVID-19 in BCG vaccinated versus non vaccinated patient population [26]. In line with this, we did
329 not observe a correlation between IgG positivity and BCG vaccination.
330 Intriguingly, we observed an inverse correlation between induction of an antibody response and
331 smoking habit. This may indicate either a lower incidence of SARS-CoV-2 infection in smokers, or
332 their inability to induce an immune response to the virus. The former is more likely as a large study
333 (114,545 individuals) in Israel recently showed that the risk of SARS-CoV-2 positive testing in
334 smoking individuals is reduced by half [27]. When analyzing the concentrations of IgG in plasma, we
335 found no differences between males and females, nor in smoking habits. However, we observed that
336 the presence of some symptoms such as fever, cough, muscular pain, astenia, anosmia/dysgeusia and
337 pneumonia correlated with higher levels of IgG than in subjects without these symptoms. In addition,
338 we found that the presence of comorbidities did not affect IgG plasma levels except for cirrhosis.
339 Subjects with cirrhosis had an inverse correlation with IgGs but the number of subjects was very low
340 and this finding needs to be confirmed. The significance of this is unknown, but the finding that
341 cirrhotic patients have higher risk of severe COVID [28] may suggest that this condition may affect the
342 correct development of antibodies. Finally, we found that although very few subjects had anti-
343 pneumoccocal vaccination, these had a reduced level of IgG, while there was no difference among
344 those vaccinated with flu vaccine. A recent study has shown an inverse correlation between
345 nasopharyngeal swab positivity and flu and pneumococcus vaccinations suggesting protection in
346 vaccinated individuals [29]. Another report on the Italian population, based on regional and not on
347 individual data, has shown an inverse correlation between COVID-19 cases and coverage of flu

348 vaccinations, suggesting again a protective role of flu vaccination [30]. It is possible that flu vaccination,
349 by inhibiting concomitant infection, may result in a better prognosis of the SARS-CoV-2 infected
350 individuals which becomes evident only when analyzing COVID-19 cases and not asymptomatic or
351 paucisymptomatic individuals. Why individuals vaccinated against pneumococcus should produce
352 less antibodies remains to be evaluated.
353
354 In conclusion, our study has some limitations, as it is monitoring healthcare workers, and thus it does
355 not reflect a comprehensive population as a good proportion of professionals are women and there is
356 an underrepresentation of the elderly due to working age limit. However, we show that antibody
357 testing can identify the individuals that were exposed to SARS-CoV-2 and is a powerful tool to
358 retrospectively evaluate viral diffusion, even in asymptomatic individuals. Another limitation of the
359 study is that we may have missed the population of subjects which do not develop an antibody
360 response or that is reduced over time. As our study is ongoing we will assess the evolution of the IgG
361 response over a planned follow up of one year, allowing for measuring the duration of the antibody
362 response. Should a second wave of SARS-CoV-2 infection occur, the wide range of IgG serology in
363 the different sites will be particularly valuable as it will allow us to assess the role of antibodies in
364 viral protection. As we also collected the PBMC from a good proportion of our cohort, this will allow
365 us to evaluate whether the T cell response lasts longer than the B cell response and may highlight
366 individuals exposed to the virus which have not seroconverted, or whose level of antibodies was
367 below 12 AU/mL. The results presented here suggest that hospital health care professionals,
368 researchers and administrative staff can provide invaluable information to assess variables affecting
369 the immune response to SARS-CoV-2 as a snapshot and during the follow-up.
370
371

372 # Methods

373 **Clinical Study**

374 The study has been approved by the international review board of Istituto Clinico Humanitas for all
375 participating institutes (clinicaltrial.gov NCT04387929). Accrual was on a voluntary basis: it started
376 on April 28th and more than 65% of employees participated as of May 16th, 2020. 7 different centers
377 participated to the study: Istituto Clinico Humanitas (ICH), Rozzano, Mi; Humanitas Gavazzeni,
378 Bergamo; Humanitas Castelli, Bergamo; Humanitas Mater Domini (HMD), Castellanza (Va);
379 Humanitas Medical Center, HMC, Varese, Mi; Humanitas University, Pieve Emanuele (Mi);
380 Humanitas San Pio X, Milano. All participants signed an informed consent and filled a questionnaire
381 (Supplementary Data S1) before blood collection. In order to be tested, subjects had to fill in the
382 questionnaire. Only after filling the questionnaire in its entirety, would the individuals be scheduled
383 for blood sampling. Hence, we obtained a 100% complete data.

384 All subjects with IgG > 12 AU/mL underwent a rinopharingeal swab for SARS-CoV-2 viral RNA
385 detection.

386

387 **SARS-CoV-2 RT-PCR**

388 Rinopharyngeal swab were tested with a commercial RT-PCR assay (AllplexTM2019-nCoV Assay
389 – Seegene, Seoul, South Korea), according to manufacturer's instruction. RNA extraction was
390 performed using Seegene Nimbus, a liquid handler workstation, Real-time PCR was run on a CFX96
391 TMDx thermocycler (Bio-Rad Laboratories, Inc, CA, USA) and subsequently interpreted by
392 Seegene's Viewer software. The test target three viral genes (*E, RdRp* and *N*).

393

394 **IgG determination**

395 For the determination of IgG anti SARS-CoV-2 the Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin,
396 Saluggia (VC), Italy) was used [31]. The method is an indirect chemiluminescence immunoassay for
397 the determination of anti-S1 and anti-S2 specific antibodies. Intra- and inter-assay coefficient of
398 variation are <1.9% and <3.7% respectively. In the datasheet of the test, in a cohort of 304 COVID-
399 19 patients 97.5% of the samples above 15 AU/mL and 86% of those with IgG>12 AU/mL resulted
400 positive for neutralizing antibodies with a titer >1:40 in the Plaque Reduction Neutralization Test
401 (PRNT).
402 The sensitivity of the test as reported by the manufacturer is 90.4% (79.4% - 95.8%) while the
403 specificity is 98.5% (97.5% - 99.2%).
404
405 **Statistics**
406 This was a cross sectional study aimed at determining the frequency of plasma anti- SARS-CoV-2
407 IgG antibodies in nearly 4000 (3985) employees of 7 different healthcare facilities located in
408 Lombardy.
409 The serological determination was offered to all the employees of the involved sites and the
410 anticipated refusal rate was assumed to be 10-15%. The overall IgG positivity was assumed to be
411 around 10-15% (between 400-600 subjects).
412 Primary endpoint was the number of test positive subjects. Given the study size, the study was able
413 to estimate the overall positivity with a width of 95% confidence interval equal to 2% and the
414 positivity for subgroups of at least 200 patients with a width of 95% confidence interval equal to 9%.
415 No power analysis was performed to calculate the sample size.
416 As secondary endpoints we aimed to investigate the factors associated to plasma anti-SARS-CoV-2
417 IgG positivity.

418 Basic demographic characteristics, including age, sex, smoking status, comorbidities, previous
419 vaccinations and symptoms were recorded and their association with IgG positivity was tabulated in
420 contingency tables and described by means of relative and absolute frequencies.
421 The association between these characteristics and IgG positivity was assessed by univariate logistic
422 model and measured with the odds ratio (OR) and 95% Confidence Interval (CI) for each factor. A
423 multivariable analysis, was also performed in order to assess the effect of characteristics of interest
424 after adjustment for the other variables.
425 Furthermore, since our data have clustered structures as patients were clustered within hospitals, a
426 multilevel model was also used to analyse data. The binary outcome (positive vs. negative serological
427 assessment) was chosen and analysis was approached with a generalized linear model with the logic
428 link, which is the logistic regression model. In our multilevel analysis there was a patient level and
429 an hospital level.
430 We produced two models. In the first one we want to assess the effect of role, gender, age, BMI and
431 cigarette smoking on the risk of positive serology. We estimated a random intercept model for
432 hospital profiling and treat the hospital effects as random effects only. The role of subjects was
433 considered related to the hospital attributes, while the subject level attributes were age (grouped in
434 >60, ≤60 years) and gender, BMI (≤20, ≤25, ≤30, ≤35, >35) and number of smoked cigarettes/day
435 (no,≤10, ≤20 >20). BMI and cigarette smoking were considered as continuous variables. The others
436 variables are all categorical. The interaction term of age*gender was included in the model.
437 In the second one we explored the relationship between vaccinations, symptoms and serological
438 positivity, after adjustment for the previous factors, still considering a hierarchical model. This was
439 obtained adding the symptoms, defined as binary variables, to the previous models. Summary
440 statistical measures were the odds ratio with relative confidence interval. SAS GLIMMIX procedure
441 (SAS© 9.4 release) was used for the purpose of analysis.

442 The same approach was used also for analysis of plasma levels. SAS Mixed procedure (SAS© 9.4
443 release) was used for the purpose of analysis.
444 Kruskal–Wallis and non-parametric tests for trend (Cuzick's and Mantel-Haenzel test, when
445 appropriate) have been used for multiple comparisons using Prism 8 Graphpad. For plasma levels,
446 odds ratio and relative 95%CI based on Wald Test presented in the figures were calculated using
447 logistic model applied to ordinal data.
448

449 **Data availability**

450 Data supporting the findings of this study are available within the paper and its Supplementary
451 Information files. All other data are available from the corresponding author upon reasonable
452 requests.
453

454 **References**

455 1 Wang, W. *et al.* Detection of SARS-CoV-2 in Different Types of Clinical Specimens.
456 *JAMA*, doi:10.1001/jama.2020.3786 (2020).
457 2 Xie, X. *et al.* Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-
458 PCR Testing. *Radiology*, 200343, doi:10.1148/radiol.2020200343 (2020).
459 3 Ai, T. *et al.* Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019
460 (COVID-19) in China: A Report of 1014 Cases. *Radiology*, 200642,
461 doi:10.1148/radiol.2020200642 (2020).
462 4 Di Paolo, M. *et al.* False-negative RT-PCR in SARS-CoV-2 disease: experience from an
463 Italian COVID-19 unit. *ERJ Open Res* **6**, doi:10.1183/23120541.00324-2020 (2020).
464 5 Li, Y. *et al.* Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients
465 clinically diagnosed with COVID-19. *J Med Virol* **92**, 903-908, doi:10.1002/jmv.25786
466 (2020).
467 6 Lippi, G., Simundic, A. M. & Plebani, M. Potential preanalytical and analytical
468 vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clin*
469 *Chem Lab Med*, doi:10.1515/cclm-2020-0285 (2020).

470 7 Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat*
471 *Med*, doi:10.1038/s41591-020-0897-1 (2020).
472 8 Xiang, F. *et al.* Antibody Detection and Dynamic Characteristics in Patients with COVID-
473 19. *Clin Infect Dis*, doi:10.1093/cid/ciaa461 (2020).
474 9 Huan Ma, W. Z., Hongliang He, Dan Zhao, Yunru Yang, Dehua Jiang, Peigen Yingjie,
475 Weihuang He, Changcheng Zhao, Ruting Yi, Xiaofang Wang, Bo Wang, Yuanhong Yun
476 Yang, Arnaud John Kombe Kombe, Chengchao Ding, Jiajia Xie, Yong Gao, Linzhao
477 Cheng1, Yajuan Li, Xiaoling Ma, Tengchuan Jin. COVID-19 diagnosis and study of serum
478 1 SARS-CoV-2 specific IgA, IgM and IgG by chemiluminescence immunoanalysis.
479 *MedRXiv*, doi:https://doi.org/10.1101/2020.04.17.20064907 (2020).
480 10 Wolfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature*,
481 doi:10.1038/s41586-020-2196-x (2020).
482 11 B, L. Serology characteristics of SARS-CoV-2 infection since the exposure and post
483 symptoms onset. doi:10.1101/2020.03.23.20041707.
484 12 Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease
485 2019. *Clin Infect Dis*, doi:10.1093/cid/ciaa344 (2020).
486 13 Dioscoridi, L. & Carrisi, C. Covid-19 exposure risk for family members of healthcare
487 workers: an observational study. *Int J Infect Dis*, doi:10.1016/j.ijid.2020.06.106 (2020).
488 14 Onder, G., Rezza, G. & Brusaferro, S. Case-Fatality Rate and Characteristics of Patients
489 Dying in Relation to COVID-19 in Italy. *JAMA*, doi:10.1001/jama.2020.4683 (2020).
490 15 Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus
491 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From
492 the Chinese Center for Disease Control and Prevention. *JAMA*, doi:10.1001/jama.2020.2648
493 (2020).
494 16 Jin, J. M. *et al.* Gender Differences in Patients With COVID-19: Focus on Severity and
495 Mortality. *Front Public Health* **8**, 152, doi:10.3389/fpubh.2020.00152 (2020).
496 17 Wu, F. W., A, Liu, M. Wang, O, Chen, J, ..Jinghe Huang. Neutralizing antibody responses
497 to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *MedXriv*,
498 doi:10.1101/2020.03.30.20047365 (2020).
499 18 Klein, S. *et al.* Sex, age, and hospitalization drive antibody responses in a COVID-19
500 convalescent plasma donor population. *medRxiv*, doi:10.1101/2020.06.26.20139063 (2020).

501 19 Sood, N. *et al.* Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los
502 Angeles County, California, on April 10-11, 2020. *JAMA*, doi:10.1001/jama.2020.8279
503 (2020).
504 20 Rivett, L. *et al.* Screening of healthcare workers for SARS-CoV-2 highlights the role of
505 asymptomatic carriage in COVID-19 transmission. *Elife* **9**, doi:10.7554/eLife.58728 (2020).
506 21 Lavezzo, E. *et al.* Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'.
507 *Nature*, doi:10.1038/s41586-020-2488-1 (2020).
508 22 Ni, L. *et al.* Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in
509 COVID-19 Convalescent Individuals. *Immunity* **52**, 971-977 e973,
510 doi:10.1016/j.immuni.2020.04.023 (2020).
511 23 Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with
512 COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415,
513 doi:10.1016/j.cell.2020.05.015 (2020).
514 24 Weiskopf, D. *et al.* Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19
515 patients with acute respiratory distress syndrome. *Sci Immunol* **5**,
516 doi:10.1126/sciimmunol.abd2071 (2020).
517 25 Netea, M. G. *et al.* Defining trained immunity and its role in health and disease. *Nat Rev*
518 *Immunol*, doi:10.1038/s41577-020-0285-6 (2020).
519 26 Hamiel, U., Kozer, E. & Youngster, I. SARS-CoV-2 Rates in BCG-Vaccinated and
520 Unvaccinated Young Adults. *JAMA*, doi:10.1001/jama.2020.8189 (2020).
521 27 Israel, A., Feldhamer,I, Lahad, A, Levin-Zamir, D, and Lavie, G. Smoking and the risk of
522 COVID-19 in a large observational population study. *MedrXiv*, doi:
523 https://doi.org/10.1101/2020.06.01.20118877 (2020).
524 28 Iavarone, M. *et al.* High rates of 30-day mortality in patients with cirrhosis and COVID-19.
525 *J Hepatol*, doi:10.1016/j.jhep.2020.06.001 (2020).
526 29 Noale, M. *et al.* The Association between Influenza and Pneumococcal Vaccinations and
527 SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey. *Vaccines (Basel)*
528 **8**, doi:10.3390/vaccines8030471 (2020).
529 30 Amato, M. *et al.* Relationship between Influenza Vaccination Coverage Rate and COVID-
530 19 Outbreak: An Italian Ecological Study. *Vaccines (Basel)* **8**,
531 doi:10.3390/vaccines8030535 (2020).

31 Bonelli, F. *et al.* Clinical And Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively. *J Clin Microbiol*, doi:10.1128/JCM.01224-20 (2020).

Acknowledgments

This work was partially supported by a philantropic donation by Dolce & Gabbana and by the Italian Ministry of Health (Ricerca corrente).

We would like to thank all the employees that volunteered to participate to this study, all the nurses and personnel that collected the samples and the laboratory technicians that run the serological and rinopharyngeal tests. We would also like to thank the Humanitas management and staff, Dr Patrizia Meroni, who warmly supported this study for the safety of the employees. Dr Alice Bertocchi for critical reading of the manuscript.

Author contribution

M.T.S. coordinated the laboratory analyses and helped writing the manuscript; E.A.: coordinated the recruitment and sampling of subjects and participated in clinical study design; V.T.: performed the statistical analysis and helped writing the manuscript; S.C.: helped in analyzing the data; C.P.: contributed to data analysis and manuscript writing; M.S.: carried out the laboratory analyses; M.T.: participated in writing the clinical protocol; M.C.: coordinated the study for the Bergamo sites; A.M.: helped writing the manuscript and designing the study protocol; M.R.: conceived the study, analyzed the data and wrote the manuscript.

Competing interests

The authors declare no competing interests.

557 ## Figure legends

558 **Figure 1. Distribution of IgG positivity (≥12 AU/mL) across different geographical areas and**
559 **healthcare facilities in Lombardy, Italy.**

560 Employees from 7 different healthcare facilities were analyzed for their anti-SARS-CoV-2 IgG
561 positivity. Pie charts show the percentage of negative subjects (IgG <12 AU/mL) (orange) and that
562 of positive subjects (IgG ≥12 AU/mL) (blue) in each site: Istituto Clinico Humanitas (ICH), Rozzano
563 (MI); Humanitas Gavazzeni, Bergamo; Humanitas Castelli, Bergamo; Humanitas Mater Domini
564 (HMD), Castellanza (VA); Humanitas Medical Center (HMC), Varese (VA); Humanitas University
565 (HU), Pieve Emanuele (MI); Humanitas San Pio X, Milan, (MI).

566

567 **Figure 2. Frequency of IgG positivity (IgG ≥ 12 AU/mL) by age.**

568 a, b, Histograms show the number (a) and the percentage (b) of positive individuals (IgG ≥ 12
569 AU/mL) divided by age range and sex on the whole population regardless of site; in b, *p*-values were
570 determined using Cuzick's test for trend. $p = 0.0374$ (total); $p = 0.0008$ (female); $p = 0.1498$ (male);
571 $p = 0.0024$ (interaction).

572

573 **Figure 3. Distribution of the IgG ≥12 and IgG<12 populations versus the number of symptoms**

574 a, c, Distribution of the IgG positive individuals (IgG ≥ 12 AU/mL) as number of individuals (a) or
575 percentage of the population (c) versus the number of self-reported symptoms. The curve that best
576 interpolated the data was a sigmoidal, four parameter logistic curve whereby X is the number of
577 symptoms (R^2=0.97). b, d, Distribution of the IgG negative individuals (IgG < 12 AU/mL) as number
578 of individuals (b) or percentage of the population (d) versus the number of self-reported symptoms.
579 The curve that best interpolated the data was exponential (R^2=0.9975).

580

581 **Figure 4. Distribution of IgG plasma levels in the different populations.**

582 a, Distribution of IgG plasma levels in the cohort of IgG positive individuals (IgG ≥ 12 AU/mL)
583 negative or positive for the rinopharyngeal swab or ascertained COVID-19 disease. b, Distribution
584 of IgG plasma levels in IgG positive individuals (IgG ≥ 12 AU/mL) divided by sex. c, Distribution
585 of IgG plasma levels in IgG positive individuals (IgG ≥ 12 AU/mL) divided by age ranges and sex.
586 In a and b *p*-values were determined using Cochran Mantel-Haenzel test for trend. In c, Cuzick's test
587 for trend was used: $p = 0.0002$ (total); $p = 0.0085$ (female); $p = 0.008$ (male); $p = 0.4192$ (interaction).

588

589 **Figure 5. Distribution of IgG plasma levels in relation to symptoms**

590 a, Distribution of IgG plasma levels versus the number of self-reported symptoms in IgG positive
591 individuals (IgG ≥ 12 AU/mL). b, Distribution of IgG plasma levels versus the number of self-
592 reported symptoms in IgG negative individuals (IgG < 12 AU/mL). c, Association between symptoms
593 and IgG plasma levels. $p<0.0001$, LR test for global null hypothesis. Odds ratio (OR) calculated with
594 logistic regression for ordinal data. d, Analysis of plasma levels of the whole population in relation
595 to a combination of symptoms, $p<0.0001$. Odds ratio (OR) calculated with logistic analysis for
596 ordinal data. e, Distribution of IgG plasma levels versus selected symptoms (alone or in combination)
597 in individuals with IgG ≥12 AU/mL. *p*-values evaluated using Kruskal–Wallis test with Dunn's post-
598 hoc test. f, Analysis of plasma levels of positive subjects (IgG≥12) in relation to a combination of
599 symptoms, $p=0.0004$. Odds ratio (OR) calculated with logistic analysis for ordinal data.


HMC
3%
HMD
3,8%
Gavazzeni
35%
Castelli
43%
San Pio X
6,4%
ICH
9%
HU
7,8%
Milano
Bergamo
Brescia
Monza
Como
Varese
Lecco
Lugano
Locarno
Bellinzona
Sondrio
Tirano
Bormio
Livigno
Solda
Bolzano
Trento
Rovereto
Riva del Garda
Limone Sul Garda
Sirmione
Desenzano del Garda
Verona
Mantova
Cremona
Piacenza
Pavia
Novara
Alessandria
Tortona
Parma
Reggio Emilia
Carpi
Modena
Parco Naturale Adamello Brenta Geopark
San Maurizio

Figure 1


a
N. IgG ≥ 12 by Age
N. IgG positive Individuals
200
150
100
50
0
Total
Females
Males
20-30
31-40
41-50
51-60
>60
b
% IgG ≥ 12 by Age
% IgG positive individuals
20
15
10
5
0
Total
Females
Males
20-30
31-40
41-50
51-60
>60

Figure 2


a
N. symptoms - Individuals IgG ≥ 12
N. Individuals
N. symptoms
b
N. symptoms - % Individuals IgG ≥ 12
% Individuals
N. symptoms
c
N. symptoms - Individuals IgG < 12
N. Individuals
N. symptoms
d
N. symptoms - % Individuals IgG < 12
% Individuals
N. symptoms

Figure 3


a
IgG positivity or negativity to rinopharyngeal swab
p = 0.7951
1000
100
10
IgG plasma levels
IgG ≥ 12 Swab Neg
IgG ≥ 12 Swab Pos
Covid population
b
IgG all males vs females
p = 0.0756
1000
100
10
IgG plasma levels
Females
Males
c
IgG levels by age IgG ≥ 12
p = 0.0002
1000
100
10
IgG plasma levels
21-30
31-40
41-50
51-60
>61
Age
IgG levels by age Females IgG ≥ 12
p = 0.0085
1000
100
10
IgG plasma levels
21-30
31-40
41-50
51-60
>61
Age
IgG levels by age Males IgG ≥ 12
p = 0.008
1000
100
10
IgG plasma levels
21-30
31-40
41-50
51-60
>61
Age

Figure 4


a
N. symptoms - Average IgG ≥ 12
IgG plasma levels
N. symptoms
b
N. symptoms - Average IgG <12
IgG plasma levels
N. symptoms
c
Odds Ratios with 95% Wald Confidence Limits
Fever
Fever-like
Cough
Sorethroat
Muscular pain
Asthenia
Anosmia/dysgeusia
Gastrointestinal disorder
Conjunctivitis
Dyspnea
Chest pain
Tachycardia
Pneumonia
Other symptoms
Odds Ratio
d
Odds Ratios with 95% Wald Confidence Limits
IgG < 12
Dyspnea vs No symptoms
Anosmia/dysgeusia AND Dyspnea vs No symptoms
Fever AND Anosmia/dysgeusia AND dyspnea vs No symptoms
Fever AND Anosmia/dysgeusia vs No symptoms
Other combo vs No symptoms
Odds Ratio
e
Combination of symptoms IgG ≥ 12
p=0.4649
IgG plasma levels
Fever and anosmia/dysgeusia
Fever and anosmia/dysgeusia and dyspnea
Anosmia/dysgeusia and Dyspnea
Dyspnea
f
Odds Ratios with 95% Wald Confidence Limits
IgG ≥ 12
Dyspnea vs No symptoms
Anosmia/dysgeusia AND Dyspnea vs No symptoms
Fever AND Anosmia/dysgeusia AND dyspnea vs No symptoms
Fever AND Anosmia/dysgeusia vs No symptoms
Other combo vs No symptoms
Odds Ratio

Figure 5